pharmaphorum

SEPTEMBER 27, 2022

Ben Hargreaves finds that the next step to enhance these treatments further could be to find synergies with emerging therapies employing similar modes of action, such as therapeutic cancer vaccines. One area that is becoming more widely discussed with the potential to be added to this group is that of therapeutic cancer vaccines.

Vaccines 97

Vaccines Immunity Immunization 97

Express Pharma

AUGUST 16, 2024

The biopharmaceutical industry remained resilient in the second quarter (Q2) of 2024 as global markets and investor optimism improved with anticipation of a potential interest rate cut from the US Federal Reserve. trillion as on 31 March 2024 to $4 trillion as on 30 June 2024, reveals GlobalData. AstraZeneca reported a 15.5

Diabetes 98

Diabetes Immunity Immunization Vaccines 98

Express Pharma

JUNE 9, 2024

GSK announced that the US FDA has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 to 59 years of age who are at increased risk. This antigen is combined with GSK’s proprietary AS01E adjuvant.

Vaccines 111

Vaccines Immunity Immunization Diabetes 111

Digital Pharmacist

SEPTEMBER 20, 2023

The Medicare Open Enrollment period for 2024 is quickly approaching – this is a critical time for both your patients and your pharmacy. Below is a breakdown of what you need to be aware of when assisting patients with 2024 open enrollments, as well as a few tips on how your pharmacy can prepare for this busy time at the pharmacy.

Independent Pharmacies 105

Independent Pharmacies Nursing Homes Immunity Immunization 105

Pharmacy Times

SEPTEMBER 25, 2023

For community pharmacists, cooler temperatures, school buses on the roads and Friday night football are not just signs of a changing season – they are indicators that patients will soon be seeking vaccinations for the 2023-2024 respiratory illness season.

Vaccines 59

Vaccines Immunity Immunization 59

Pharmacy Times

SEPTEMBER 13, 2023

The CDC emphasized the need for protein-based vaccine options in endorsing a vote by the Advisory Committee on Immunization Practices for the universal recommendation of the 2023-2024 monovalent, XBB containing COVID-19 vaccines.

Vaccines 55

Vaccines Immunity Immunization 55

Express Pharma

JULY 1, 2024

AstraZeneca stated on July, 1 2024, that the European Union drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, sipavibart, for an accelerated assessment. An accelerated assessment aims to speed up the EMA’s review of a market authorisation application.

Vaccines 103

Vaccines Immunity Immunization 103

Pharmacy Times

JANUARY 22, 2024

The schedule includes RSV vaccination, along with updated versions of the COVID-19 vaccine.

Vaccines 50

Vaccines Immunity Immunization 50

Express Pharma

SEPTEMBER 4, 2024

Whilst most cases are mild and resolve within a few weeks, some people – particularly children, pregnant women, and those with suppressed immune systems – may endure more severe disease, which can be fatal. The SPRP covers a six-month period from September 2024 to February 2025.

Vaccines 104

Vaccines Immunity Immunization 104

Pharmaceutical Business Review

SEPTEMBER 2, 2024

The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. Following the EUA, the vaccine is also recommended by the US Centers for Disease Control and Prevention (CDC). Our updated vaccine targets JN.1, 1.” “Our updated vaccine targets JN.1,

Vaccines 59

Vaccines Adverse Reactions Immunity Immunization 59

European Pharmaceutical Review

JUNE 28, 2024

The post <em>European Pharmaceutical Review </em> Issue 3 2024 appeared first on European Pharmaceutical Review.

Research Laboratories 52

Research Laboratories Vaccines Drug Development Immunity 52

Pharmaceutical Business Review

DECEMBER 20, 2023

This vaccine is designed for preventing infections caused by the bacterial pathogen Staphylococcus aureus (S. LimmaTech intends to commence Phase I clinical trials for the vaccine candidate in 2024, with the option to secure complete worldwide rights post the trial’s outcome. aureus infection. aureus infection.

Vaccines 59

Vaccines Immunity Immunization 59

European Pharmaceutical Review

NOVEMBER 10, 2023

The US Food and Drug Administration (FDA) has approved Valneva SE’s IXCHIQ ® , the first chikungunya vaccine to be authorised in the world. The single-dose, live-attenuated vaccine is indicated for preventing chikungunya virus disease in individuals over 18 years old who are at increased risk of contracting the virus.

Vaccines 52

Vaccines Adverse Reactions Immunity Immunization 52

European Pharmaceutical Review

JUNE 13, 2024

In April 2024, Ocugen received US Food and Drug Administration (FDA) clearance to initiate the Phase III liMeliGhT clinical trial for OCU400 for retinitis pigmentosa. In May 2024, Ocugen announced the second cohort (medium dose) completed dosing in the dose-escalation phase. Tell us about Ocugen’s lead programme, OCU400.

Immunity 145

Immunity Immunization Vaccines 145

European Pharmaceutical Review

MAY 7, 2024

percent compound annual growth rate (CAGR) between 2024 to 2029. Injectable vaccines activate the immune system to help to prevent infectious conditions such as influenza. A new report by MarketsandMarkets has predicted that the injectable drug delivery market will reach an 8.6 The market is anticipated to value $1139.4

Vaccines 94

Vaccines Compounding Immunity Immunization 94

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20.

Vaccines 64

Vaccines Immunity Immunization 64

Pharmaceutical Business Review

APRIL 3, 2024

The Centers for Disease Control and Prevention (CDC) had provided interim guidance for the vaccine’s pre- and post-exposure use during the outbreak for people at risk. The CDC estimates that two million individuals in the US are eligible for the mpox vaccination.

Vaccines 52

Vaccines Physician Offices Immunity Immunization 52

Big Molecule Watch

SEPTEMBER 22, 2023

Below we provide updates on two proceedings involving the mRNA vaccine producer Moderna. Alynlam had previously alleged that Moderna’s COVID-19 vaccine products, marketed as SPIKEVAX® infringed U.S. The deadline for an institution decision on both petitions is March 2024. Alnylam”) against Moderna, Inc., ModernaTX, Inc.,

Vaccines 50

Vaccines Immunity Immunization 50

Big Molecule Watch

OCTOBER 23, 2024

Last week, GlaxoSmithKline and Northwestern University filed separate lawsuits against Moderna, accusing its mRNA-based vaccines of patent infringement. 1:24-cv-01135 , GSK accuses Moderna’s Spikevax (R) SARS-CoV-2 S protein mRNA vaccine products of infringing U.S. In Civil Action No. Patent Nos. In Civil Action No. Patent Nos.

Vaccines 69

Vaccines Immunity Immunization 69

Express Pharma

OCTOBER 9, 2024

He addressed the CII 6th Pharma and Life Sciences Summit 2024 in New Delhi. He stressed the need for proactive R&D, particularly in developing countermeasures for future pandemics, and the necessity of preparedness through rapid vaccine development.

Vaccines 105

Vaccines Process Improvement Biosimilars Immunity 105

Integra X Files

FEBRUARY 20, 2023

The COVID-19 PHE suspended various training requirements, suspended personal visit requirements for physicians and other providers, allowed telehealth visits, and made vaccines and treatments widely available. Beginning in 2024, the administration fee for COVID-19 immunizations will be in line with other Medicare Part B vaccines.

Nursing Homes 89

Nursing Homes Vaccines Controlled Substances Hospitals 89

PharmaShots

FEBRUARY 20, 2023

Shots: The USPTO issued the company a patent for its transformative technology to produce orally delivered animal vaccines by the number Patent US-11566255-B2, "Expression of PEDV Sequences in Plants and Plant Produced Vaccine for Same" on the 31st of Jan 2023 The patent covers foundational technology for the company’s first vaccine (..)

Vaccines 40

Vaccines Immunization Immunity 40

Pharmaceutical Business Review

NOVEMBER 27, 2024

The vaccine, which is approved for adults currently, may soon be available for use in adolescents aged 12 to 17 years if the extension is granted. In the US and Canada, the application also includes two-year antibody persistence data, demonstrating that 97% of subjects maintained their immune response after 24 months.

Vaccines 52

Vaccines Labelling Immunity Immunization 52

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Vaccines 59

Vaccines Immunity Immunization Medical Schools 59

pharmaphorum

JULY 27, 2021

The FDA has approved GlaxoSmithKline’s shingles vaccine Shingrix for use in people aged under 50 who are immunocompromised – a key step in the UK drugmaker’s plan to build the shot into a £4 billion-plus product in the next five years. Shingrix pulled in sales of £2 billion (around $2.8

Vaccines 52

Vaccines Immunity Immunization 52

Big Molecule Watch

DECEMBER 13, 2024

Currently in preclinical development, DB-1324 was developed using DualityBios proprietary and clinically validated Duality Immune Toxin Antibody Conjugate platform. Merus and Partner Therapeutics announce an exclusive license agreement to commercialize NRG1+ cancer antibody, Zeno On December 2, 2024 Merus N.V.

Vaccines 45

Vaccines Immunity Immunization 45

Express Pharma

JUNE 12, 2024

Covid-19 promoted India to the centre stage of global vaccine export as the consumerisation of health providing an impetus for vaccines and prompt approvals. Additionally, the Department of Pharmaceuticals, Government of India, directive requires strict compliance with the Uniform Code for Marketing Practices 2024.

Generic Medicine 105

Generic Medicine Vaccines Diabetes Immunity 105

Express Pharma

JUNE 21, 2024

Covid-19 promoted India to the centre stage of global vaccines export as consumerisation of health providing an impetus for vaccines and prompt approvals. Additionally, the Department of Pharmaceuticals, Government of India, directive requires strict compliance with the Uniform Code for Marketing Practices 2024.

Generic Medicine 102

Generic Medicine Vaccines Diabetes Immunity 102

Pharmaceutical Technology

JANUARY 6, 2023

If approved, nirsevimab will become the first single-dose preventative against RSV lower respiratory tract disease for the 2023/2024 RSV season in the US. The regulatory body has assigned a Prescription Drug User Fee Act (PDUFA) date for its decision in the third quarter of this year.

Immunity 59

Immunity Immunization Vaccines 59

Pharmaceutical Technology

MAY 24, 2023

Morphogenesis’s technologies include Immune Fx (IFx) personalised cancer vaccines and tumour microenvironment (TME) modulators. IFx has been designed to activate an innate immune response against tumour antigens that are patient-specific. Morphogenesis’ lead personalised cancer vaccine, IFx-Hu2.0,

Immunity 52

Immunity Immunization Vaccines 52

Pharmaceutical Technology

JULY 29, 2022

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

Vaccines 52

Vaccines Packaging Immunity Immunization 52

European Pharmaceutical Review

JUNE 27, 2023

difficile infection by the end of 2024 and will be announcing first patient dosed in the Phase II clinical trial of VE202 for ulcerative colitis (UC) shortly too. He has also held the role of Vice President and Therapeutic Area Head, Vaccine Clinical Research at Merck & Co.

Immunity 105

Immunity Immunization Chemotherapy Vaccines 105

PharmaShots

JUNE 1, 2023

PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. We reported at ESMO-IO the analysis of immune response of the first 3 cohorts of patients.

Immunity 40

Immunity Immunization Vaccines Health and Personal Care Stores 40

Quality Matters

JUNE 17, 2024

Types of biologics include hormone therapies, transplant tissues, monoclonal antibodies, vaccines and cell and gene therapies. They can also help stimulate the body’s immune system to attack disease-causing cells or organisms. How do biologics work? Different kinds of biologics exert their therapeutic effects in different ways.

Biosimilars 52

Biosimilars Dosage Immunity Immunization 52

European Pharmaceutical Review

AUGUST 29, 2024

5 Preventing spread of the mpox virus To help prevent more cases of the virus, the CDC recommended that individuals who have had exposure to the virus and those at risk of infection are given two doses of biotech Bavarian Nordic’s vaccine JYNNEOS ® (MVA-BN).

Vaccines 98

Vaccines Immunity Immunization Pharmaceutical Companies 98

PharmaShots

APRIL 25, 2023

Through its internal development, partnerships, and acquisitions, the company has put together four technology platforms that primarily focus on antibodies, T cells, innate immunity, and siRNAs. Currently, AstraZeneca is conducting a P-I clinical trial for the evaluation of ALXN2030 in healthy individuals with data anticipated in 2024.

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Diabetes Packaging Immunity 40

pharmaphorum

SEPTEMBER 1, 2021

Johnson & Johnson’s HIV vaccine candidate has failed its first major efficacy test, as it was unable to protect women against infection with the virus in a phase 2b trial carried out in sub-Saharan Africa. ” The post J&J vaccine fails to protect women against HIV infection appeared first on.

Vaccines 59

Vaccines Immunity Immunization 59